AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

DUSA Pharmaceuticals Reports Third Quarter Corporate Highlights And Financial Results; Levulan PDT Product Launch Update.

Business Wire

| November 14, 2000 | COPYRIGHT 2000 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Health/Medical Writers

WILMINGTON, Mass.--(BW HealthWire)--Nov. 14, 2000

DUSA Pharmaceuticals (NASDAQ:DUSA)

DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA) announced today its third quarter corporate highlights and financial results, along with an update on the LEVULAN(R) PDT product launch.

Corporate highlights and update on the LEVULAN(R) PDT product launch

FDA Approval/Product Launch

As previously reported, late in the third quarter, DUSA achieved its most important milestone to date, with the United States commercial launch of its first products, the LEVULAN(R) (aminolevulinic acid HCl) KERASTICK(R) 20% Topical Solution with Photodynamic Therapy (PDT) for the treatment of non-hyperkeratotic actinic keratoses (AKs) of the face or scalp using the Company's BLU-U(TM) brand light source. The launch, by Berlex Laboratories, Inc., the US affiliate of DUSA's dermatology marketing partner, Schering AG of Germany, occurred almost immediately following receipt of FDA approval for DUSA's PMA Supplement, covering the commercial version of the BLU-U(TM).

Related articles from newspapers, magazines, journals, and more
DUSA Pharmaceuticals Reports Accelerated Termination of Dermatology Agreement...
Press release article from: Business Wire August 27, 2002 700+ words
...announced notice of termination that DUSA received on June 6, 2002, DUSA(R) and Schering AG have now finalized a termination agreement...AG, the completion of studies by Schering AG, the approach of DUSA's marketing plans, intention to...
Dusa Reports Receipt Of $15,000,000 From Schering AG.
Press release article from: Business Wire December 21, 2000 700+ words
...going basis, DUSA will receive royalties...supply fees from Schering AG based upon the sales...partnership with Schering AG, while for internal indications, DUSA will work independently...statements relate to DUSA's receipt of royalties...supply fees from Schering ...
DUSA Reports That It Will Be Reacquiring The Rights To Its Levulan PDT...
Press release article from: Business Wire June 7, 2002 700+ words
...WIRE)--June 7, 2002 DUSA Pharmaceuticals, Inc. (NASDAQ NMS: DUSA) announced today that it has received from Schering AG, Germany, its marketing...the next twelve months. DUSA will work with Schering AG, Germany, and its US affiliate...
Schering AG and DUSA Sign Levulan PDT Dermatology Agreement.
Press release article from: Business Wire November 23, 1999 700+ words
...Nov. 23, 1999-- Schering AG and DUSA Pharmaceuticals, Inc...Executive Officer of DUSA. "Schering has a long...that Schering has chosen DUSA's Levulan(R) PDT...Executive Directors of Schering AG, emphasized: "This...
Press Release: Dusa Pharmaceuticals reports accelerated termination of...
News wire article from: Asia Africa Intelligence Wire August 27, 2002 700+ words
...NewsBase: Press Release) Dusa Pharmaceuticals Inc reported...the field of dermatology from Schering AG, its former dermatology marketing...notice of termination that Dusa Pharmaceuticals received on 6 Jun 2002, Dusa Pharmaceuticals and Schering...
DUSA Pharmaceuticals Reports Third Quarter Corporate Highlights And Financial...
Press release article from: Business Wire November 12, 2002 700+ words
...on June 7, 2002, DUSA received a Notice of Termination from Schering AG related to the Marketing...in transition from Schering AG to DUSA. End-user sales...marketing efforts from Schering AG to DUSA. DUSA has now started...
DUSA Pharmaceuticals Reviews and Updates Progress at Annual Meeting.
Press release article from: Business Wire June 15, 2000 700+ words
...additional indications. With Schering AG's strong commitment to dermatology...worldwide marketing capabilities, DUSA feels that Schering AG is an ideal dermatology partner...PD) development program. DUSA and Schering AG are jointly developing Levulan...
DUSA Pharmaceuticals Reports First Quarter Corporate Highlights and Financial...
Press release article from: Business Wire May 10, 2000 700+ words
...from the doctors. DUSA and Schering AG are also developing...development program with Schering AG. DUSA has also been planning...indications through DUSA corporate studies...companies (including Schering AG) and/or through...
CORRECTION: DUSA Pharmaceuticals Reports First Quarter Corporate Highlights and...
Press release article from: Business Wire May 12, 2000 700+ words
...from the doctors. DUSA and Schering AG are also developing...development program with Schering AG. DUSA has also been planning...indications through DUSA corporate studies...companies (including Schering AG) and/or through...
DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2002 Financial...
Press release article from: Business Wire March 11, 2003 700+ words
...Supply Agreement with Schering AG of Germany, covering DUSA's Levulan(R) PDT...other rights granted to Schering AG under the agreement. DUSA has now begun to institute...termination of the Schering AG agreement, DUSA recorded the following...
For more facts and information, see all results

Source: HighBeam Research, DUSA Pharmaceuticals Reports Third Quarter Corporate Highlights And...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA